Navigation Links
Sangamo BioSciences Announces Presentation At Regen Med Investor Day

RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.


Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray , this flagship event features 16 of the regenerative medicine field's leading small- and mid-cap companies.

The following are specific details regarding Sangamo BioSciences' presentation at the conference:Event:

ARM's Regen Med Investor DayDate:

April 17, 2013Time:

2:45pm ESTLocation:

Harmonie Club, 4 East 60th Street, New York, NY 10022The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on both the Sangamo and ARM websites after the event.

The event also includes disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote-style talks by Jeff Jonas , President of Shire Regenerative Medicine and Kieran Murphy , President and CEO, GE Healthcare Life Sciences.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at Please visit for more information.

About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
2. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Reports First Quarter 2012 Financial Results
8. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
(Date:6/22/2016)... 22, 2016  According to Kalorama Information, the ... (NGS) market include significant efforts in automation as ... accessible and affordable sequencers, say the healthcare market ... consumables including sample prep materials.  The healthcare market ... Preparation for Next Generation Sequencing (NGS) , highlights ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):